Abstract: Visibly transparent photovoltaic devices are disclosed, such as those are transparent to visible light but absorb near-infrared light and/or ultraviolet light. The photovoltaic devices make use of transparent electrodes and near-infrared absorbing visibly transparent photoactive compounds, optical materials, and/or buffer materials.

Abstract: Compound of formula (4) or formula (5), wherein L is a neutral ligand, preferably a nitrogen-containing heterocyclic carbene (NHC) such as carbene containing at least two nitrogen atoms, a cyclic aminoalkyl carbene (CAAC) or a bicyclic aminoalkyl carbene (BICAAC); R1, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are, independently, H, unbranched or branched C1-20 alkyl, C5-9 cycloalkyl, unbranched or branched C1-20 alkoxy, optionally bearing one or more halogen atoms, respectively; or aryl, optionally substituted with one or more of unbranched or branched C1-20 alkyl, C5-9 cycloalkyl, unbranched or branched C1-20 alkoxy, aryl, aryloxy, unbranched or branched C1-20 alkylcarbonyl, arylcarbonyl, unbranched or branched C1-20 alkoxycarbonyl, aryloxycarbonyl, heteroaryl, carboxyl, cyano, nitro, amido, aminosulfonyl, N-heteroarylsulfonyl, unbranched or branched C1-20 alkylsulfonyl, arylsulfonyl, unbranched or branched C1-20 alkylsulfinyl, arylsulfinyl, unbranched or branched C1-20 alkylthio, arylthio, sulfonamide, haloge

Abstract: The present invention relates to certain tetramic acid derivatives that are suitable for use in the preparation and development of antimicrobial (e.g. antibacterial or antifungal) compositions. The present invention also relates to the use of such compounds as antimicrobial (e.g. antibacterial or antifungal agents) and, in particular, as topical antibacterial or antifungal agents.

Abstract: The invention relates to reactive ionic liquids containing organic cations with groups or substituents which are susceptible to electrochemical reduction and anions obtained from fluoroalkyl phosphates, fluoroalkyl phosphinates, fluoroalkyl phosphonates, acetates, triflates, imides, methides, borates, phosphates and/or aluminates, for use in electrochemical cells, such as lithium ion batteries and double-layer capacitors.

Abstract: A photoconductor, which contains an electrically conductive support, and at least a photoconductive layer provided over the electrically conductive support, wherein the photoconductive layer contains a compound represented by the following general formula (1): where R1, R2, R3, R4, R5 and R6 are each independently a hydrogen atom, a halogen atom, an alkyl group, an aralkyl group, an alkoxy group, or an aralkyloxy group; n, a, b, c, and d are each independently an integer of 1 to 4 and m is 1 or 2; and a plurality of R1, R2, R3, R4, R5 or R6 may be the same or different when n, m, a, b, c, or d is an integer of 2 or greater.

Abstract: A copper(I) complex is represented by the following Formula (1): [Cua(XS)b(L)c], wherein, L is triphenylphosphine, acetonitrile, tri-iso-butylphosphine, or a substituted or unsubstituted heterocyclic compound having 5 to 18 carbon atoms, a is an integer from 2 to 6, b is an integer from 2 to 6, c is an integer from 0 to 6, X is a substituted or unsubstituted aryl group, substituted or unsubstituted carbazole, or PR3, where R is a substituted or unsubstituted phenyl group or a substituted or unsubstituted cyclohexyl group.

Abstract: This invention comprises salophene-based metallic complexes. Included are metal-chelating analogues, and method of their preparation and use. These analogues have therapeutic activity including anticancer activity.

Abstract: Use of homogeneous catalytic systems which include as a pre-catalyst a complex of a Group IV metal and a salalen ligand in the polymerization of alpha-olefins, is disclosed. The alpha-olefin polymers obtained are characterized by controlled levels of tacticity. Also disclosed are novel salalen ligands and novel complexes thereof with Group IV metals.

Abstract: Disclosed are a category of platinum compounds having amino- or alkylamino-containing succinato derivatives as leaving group, or pharmaceutically acceptable salts thereof, preparation method thereof, and medicinal compositions containing the compounds. Also disclosed is a use of the compounds in treating cell proliferative diseases, especially cancers. The platinum compounds of the present invention have high water solubility and small toxic side effect.

Abstract: Provided is a curable colored composition, transmitting the light in the magenta region and absorbing the light in the cyan region. A curable colored composition comprising a metal complex in which a compound represented by formula (I) below is coordinated to a metal atom or a metal compound.

Abstract: The present invention provides, among other things, novel compounds and methods for metathesis reactions. In some embodiments, a provided compound has the structure of formula I or II. In some embodiments, the present invention provides compounds and methods for Z-selective olefin metathesis.

Abstract: Described herein are platinum-based brush-arm star polymers (Pt-BASPs), or a pharmaceutical composition thereof, for delivery of platinum-based agents, such as cisplatin. Also provided are methods and kits involving the Pt-BASPs, or a pharmaceutical composition thereof, for treating proliferative diseases such as cancers (e.g., lung cancer, head-and-neck cancer, esophagus cancer, stomach cancer, breast cancer, pancreas cancer, liver cancer, kidney cancer, or prostate cancer) in a subject.

Abstract: Described herein are compounds and methods of catalyzing ethenolysis reactions, optionally on an industrial scale. In certain embodiments, the catalysts bear cyclic alkyl amino carbene (CAAC) ligands with an ortho substituent, such as a methyl substituent, on an N-aryl ring. When used to catalyze ethenolysis reactions, certain such compounds produce a turnover number greater than 50,000.

Abstract: The compounds and the synthesis of [F-18]-labeled L-glutamic acid, [F-18]-labeled L-glutamate, their derivatives as set forth in formula (I) and their uses are described.

Abstract: The present disclosure relates to a compound comprising an aryloxy-phthalocyanine compound of group III metals, a method for preparing said compound and an article of manufacture made therefrom.

Abstract: The present disclosure relates to a compound comprising an aryloxy-phthalocyanine compound of group IV metals, a method for preparing said compound and an article of manufacture made therefrom.

Abstract: The invention provides a colored curable composition including a dipyrromethene compound having a structure in which a polymerizable group and a carboxyl group are introduced in the same molecule, a resist liquid, an ink for inkjet printing, a color filter, a method of producing a color filter, a solid-state image sensor, a liquid crystal display, an organic EL display, an image display device and a colorant compound.

Abstract: Provided is a colored composition including at least one selected from the group consisting of a compound represented by the following formula (I) and a tautomer thereof: wherein in formula (I), R2 to R5 each independently represent a hydrogen atom or a monovalent substituent; R7 represents a hydrogen atom, a halogen atom, an alkyl group, an aryl group or a heterocyclic group; Ma represents a metal or a metal compound; X3 and X4 each independently represent NR, a nitrogen atom, an oxygen atom, or a sulfur atom, wherein R represents a hydrogen atom, an alkyl group, an alkenyl group, an aryl group, a heterocyclic group, an acyl group, an alkylsulfonyl group, or an arylsulfonyl group; X5 represents a group required to neutralize the charge of Ma; a represents 1 or 2; and R8 to R17 each independently represent a hydrogen atom or a monovalent substituent, provided that at least one of R8 to R17 represents a particular polymerizable substituent.

Abstract: A colored composition including at least one selected from the group consisting of a compound represented by the following formula (I) and a tautomer thereof. In formula (I), R2 to R5 each independently represent a hydrogen atom or a monovalent substituent, R7 represents a hydrogen atom, a halogen atom, an alkyl group, or the like, Ma represents a metal or a metal compound, X3 and X4 each independently represent NR, a nitrogen atom, an oxygen atom, or a sulfur atom, R represents a hydrogen atom, an alkyl group, or the like, Y1 and Y2 each independently represent NRc, a nitrogen atom, or a carbon atom, Rc represents a hydrogen atom, an alkyl group, or the like, and R8 and R9 each independently represent an alkyl group, an alkenyl group, or the like. Z represents an atomic group that forms a nitrogen-containing ring having a specific structure.

Abstract: A colorant multimer includes, as a partial structure of a colorant moiety, a dipyrromethene metal complex compound or tautomer thereof obtained from: (i) a dipyrromethene compound represented by the following Formula (M); and (ii) a metal or a metal compound: wherein in Formula (M), R4, R5, R6, R7, R8, R9, and R10 each independently represent a hydrogen atom or a monovalent substituent.

Abstract: A maleimide-functionalized gold nanoparticle is described herein. More specifically, a maleimide-functionalized gold nanoparticle of formula (I): is described, wherein “n” and “m” are integers independently ranging from 1 to 100.

Abstract: Provided is a medicinal agent for medical applications, which can act on the function of a target cell specifically. The medicinal agent for medical applications comprises: a cell-incorporated substance that can be incorporated into a target cell specifically; and an acting substance that can act on the function of the target cell and is bound to the cell-incorporated substance.

Abstract: The present invention is directed single diasteromers of 4-fluoroglutamine having a diastereomeric excess of at least 80%. Methods of preparing the single diastereomers are also described, as well as methods of using the single diastereomers of radiolabeled 4-fluoroglutamine as imaging agent is also described.

Abstract: A colored curable composition is provided which has good developability, has excellent color purity, can be formed into a thin film, and has a high absorption coefficient. The colored curable composition includes at least one of specific dipyrromethene metal complex compounds and tautomers thereof. Also, a colored curable composition suitable for forming a color filter which is used in a liquid crystal display device or a solid-state imaging device, and a color filter using the colored curable composition and a method of producing the same are provided.

Abstract: The invention relates to C—H activated olefin metathesis catalyst compounds, the preparation of such compounds, and the use of such catalysts in the metathesis of olefins and olefin compounds, more particularly, the use of such catalysts in Z selective olefin metathesis reactions. In general, the catalyst compounds of the invention comprise a Group 8 metal (M), an alkylidene moiety (?CR1R2), or more generally (?(C)mCR1R2), an anionic ligand (X1), two or three neutral ligands (L1, L2, and L3) and a 2-electron anionic donor bridging moiety (Q*) that forms a chelate ring structure in conjunction with L1 and M.

Abstract: Embodiments of the invention are directed to ONO pincer ligands that can be in a trianionic, protonated or protonated equivalent form. The ONO pincer ligand can be combined with a transition metal comprising compound to form an ONO pincer ligand comprising transition metal complex. By choice of the ONO pincer ligand structure, the steric and electronic properties of the transition metal complexes therefrom can be controlled. The ONO pincer ligands comprise a central nitrogen atom that is disubstituted with a pair of three atom comprising bridges where the three atoms are three sp2 hybridized carbons or the three atoms are a pair of sp2 hybridized carbons and an sp3 hybridized carbon or silicon.

Abstract: The present invention provides a cathode catalyst for an air secondary cell having both excellent oxygen reduction activity and excellent water oxidation activity, and an air secondary cell that uses the catalyst. The present invention relates to a cathode catalyst for an air secondary cell in which the catalyst contains a polynuclear metal complex.

Abstract: Catalysts comprising a non-symmetrical Salan ligand with a carbazole moiety. Also disclosed are catalyst systems comprising the catalyst and an activator; methods to prepare the ligands, catalysts and catalyst systems; processes to polymerize olefins using the catalysts and/or catalyst systems; and the olefin polymers prepared according to the processes.

Abstract: A colored composition including at least one selected from the group consisting of a compound represented by the following formula (I) and a tautomer thereof. In formula (I), R2 to R5 each independently represent a hydrogen atom or a monovalent substituent, R7 represents a hydrogen atom, a halogen atom, an alkyl group, or the like, Ma represents a metal or a metal compound, X3 and X4 each independently represent NR, a nitrogen atom, an oxygen atom, or a sulfur atom, R represents a hydrogen atom, an alkyl group, or the like, Y1 and Y2 each independently represent NRc, a nitrogen atom, or a carbon atom, Rc represents a hydrogen atom, an alkyl group, or the like, and R8 and R9 each independently represent an alkyl group, an alkenyl group, or the like. Z represents an atomic group that forms a nitrogen-containing ring having a specific structure.

Abstract: Catalysts comprising salan ligands with carbazole moieties. Also, catalyst systems comprising the catalyst and an activator; methods to prepare the ligands, catalysts and catalyst systems; processes to polymerize olefins using the catalysts and/or catalyst systems; and the olefin polymers prepared according to the processes.

Abstract: A colored composition includes at least one selected from the group consisting of a compound represented by the following Formula (I) and a tautomer thereof: wherein, in Formula (I), R2 to R5 and R8 to R17 each independently represent a hydrogen atom or a monovalent substituent; pairs of R2 and R3, R4 and R5, R8 and R9, R9 and R10, R10 and R11, R11 and R12, R13 and R14, R14 and R15, R15 and R16, and R16 and R17 may each independently bond to each other to form a 5-membered, 6-membered, or 7-membered saturated ring or unsaturated ring; R7 represents a hydrogen atom, a halogen atom, an alkyl group, an aryl group, or a heterocyclic group; Ma represents a metal or a metal compound; X represents a group necessary for neutralizing the charge of Ma; L represents a single bond or a divalent linking group; and R18 represents a hydrogen atom or a methyl group.

Abstract: Provided is a colored composition including at least one selected from the group consisting of a compound represented by the following formula (I) and a tautomer thereof: wherein in formula (I), R2 to R5 each independently represent a hydrogen atom or a monovalent substituent; R7 represents a hydrogen atom, a halogen atom, an alkyl group, an aryl group or a heterocyclic group; Ma represents a metal or a metal compound; X3 and X4 each independently represent NR, a nitrogen atom, an oxygen atom, or a sulfur atom, wherein R represents a hydrogen atom, an alkyl group, an alkenyl group, an aryl group, a heterocyclic group, an acyl group, an alkylsulfonyl group, or an arylsulfonyl group; X5 represents a group required to neutralize the charge of Ma; a represents 1 or 2; and R8 to R17 each independently represent a hydrogen atom or a monovalent substituent, provided that at least one of R8 to R17 represents a particular polymerizable substituent.

Abstract: A pharmaceutically acceptable peroxovanadium(v) amine product, DmpzH[VO(02)2](Dmpz)], and its oral as well as injectable use for the treatment of Diabetes mellitus, wherein the said therapeutically stable compound is obtained by reacting V205 or vanadate with hydrogen peroxide and the amine, dimethylpyrazole (Dmpz), at pH 5.5 and temperature 0-4° C. DmpzH[VO(02)2](Dmpz)] is thus poised as a versatile insulin mimic adapted for targeting insulin signaling, stimulating adipogenesis, abrogating insulin stimulated down stream signals thereby lowering the incidence of insulin resistance and type-2 diabetes.

Abstract: Provided is a curable colored composition, transmitting the light in the magenta region and absorbing the light in the cyan region. A curable colored composition comprising a metal complex in which a compound represented by formula (1) below is coordinated to a metal atom or a metal compound.

Abstract: The present invention relates to the use of dithiocarbamate compounds and to an assembly for use in an electronic device, said assembly comprising a self-assembled monolayer of at least one dithiocarbamate compound. The present invention also relates to an electronic device including such assembly.

Abstract: This invention relates to a carbene complex of metal salt represented by the formula: [T?M(R)c]n wherein, R is a monoanionic group; c is 1 or 2; M is a Li or Mg; T is a cyclic carbene ligand; and n is selected from the group of integers comprising 1 to 24 wherein the complex has 50% or less decomposition when stored in 0.01 molar benzene at 23° C. for a period of 1 hour. This invention also relates to transition-metal-carbene complexes prepared from such carbene complexes of metal salts, where the transition-metal-carbene complex is represented by the formula: [M*(T)(L0)q(L1?)s(L2?)t]g, where M* is a transition metal from Group 6, 7, 8, 9, 10, 11 or 12, T is a cyclic carbene ligand, L0 is a neutral ligand, L1? is a monoanionic ligand, L2? is a dianionic ligand, q is 0, 1, 2, 3 or 4, s is 0, 1, 2, 3, or 4, t is 0, 1, 2, 3, or 4, g is the overall charge of the molecule. The transition-metal-carbene complexes may be used for synthesis reactions, including metathesis of olefins.

Abstract: The invention provides a dye compound having a partial structure represented by the following formula (5): wherein in formula (5), Dye represents a dye structure; G1 represents NR or an oxygen atom; G2 represents a monovalent substituent group having an ?Es? value as a steric parameter of 1.5 or more; p represents an integer from 1 to 8; when p is 2 or greater, the two or more structures represented by p may be the same or different from each other; and R represents a hydrogen atom or a monovalent substituent group.

Abstract: The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.

Abstract: Disclosed are precursors having a pyrrolecarbaldiminates ligand and methods of synthesizing the same. The pyrrolecarbaldiminates ligand may be substituted.

Abstract: Use of homogeneous catalytic systems which include as a pre-catalyst a complex of a Group IV metal and a salalen ligand in the polymerization of alpha-olefins, is disclosed. The alpha-olefin polymers obtained are characterized by controlled levels of tacticity. Also disclosed are novel salalen ligands and novel complexes thereof with Group IV metals.

Abstract: The combined use—whether by adsorption or covalent linkage—of Melatonin adjacent any bone implant or graft, preferably any calcium- and oxide-containing artificial bone graft material, and more preferably a calcium aluminate composition. Alternatively, the bone graft or implant material may be used as a scaffold for tissue engineering.

Abstract: Metal-containing complexes with general formula (1) (R1nPyr)(R2nPyr)ML1L2; or (2) [(R8XR9)(R1nPyr)(R2nPyr)]ML1L2 are disclosed; wherein M is a Group IV metal, Pyr is pyrrolyl ligand, n=1, 2 and 3, L1 and L2 are independently selected from alkoxide, amide or alkyl, L1 and L2 can be linked together, R1 and R2 can be same or different organic groups substituted at 2,3,4-positions of the pyrrole ring and are selected from the group consisting of linear and branched C1-6 alkyls, Wand R9 are independently selected from the linear or branched chain alkylene group having 2-6 carbon atoms, and X is CH2 or oxygen. Methods of using the metal complexes as precursors to deposit metal or metal oxide films used for various devices in semi-conductor industries are also discussed.

Abstract: This invention comprises salophene-based metallic complexes. Included are metal-chelating analogues, and method of their preparation and use. These analogues have therapeutic activity including anticancer activity.

Abstract: Bi-(indole-2-aceto)-iron II, also named ferrous bis(indole acetate), or a pharmaceutically acceptable salt thereof, wherein: —Fe (Iron) is substituted by another transition metal capable of bonding to two molecules of indole acetate is synthesized for medicinal purposes including treatment of solid tumor cancers and other vascular proliferative disorders. This invention also extends to the substitution of the ligands by one or more of the structural analogues of indole acetetate disclosed in this application. In certain aspects, the compositions of the invention are capable of generating both a vascular targeting effect and tumor cell cytotoxicity (e.g. by oxidative stress) in order to achieve an enhanced anti-tumor response.

Abstract: A colored curable composition is provided which has good developability, has excellent color purity, can be formed into a thin film, and has a high absorption coefficient. The colored curable composition includes at least one of specific dipyrromethene metal complex compounds and tautomers thereof. Also, a colored curable composition suitable for forming a color filter which is used in a liquid crystal display device or a solid-state imaging device, and a color filter using the colored curable composition and a method of producing the same are provided.

Abstract: A colored curable composition is provided which has good developability, has excellent color purity, can be formed into a thin film, and has a high absorption coefficient. The colored curable composition includes at least one of specific dipyrromethene metal complex compounds and tautomers thereof. Also, a colored curable composition suitable for forming a color filter which is used in a liquid crystal display device or a solid-state imaging device, and a color filter using the colored curable composition and a method of producing the same are provided.

Abstract: The invention provides a colored curable composition including a dipyrromethene compound having a structure in which a polymerizable group and a carboxyl group are introduced in the same molecule, a resist liquid, an ink for inkjet printing, a color filter, a method of producing a color filter, a solid-state image sensor, a liquid crystal display, an organic EL display, an image display device and a colorant compound.

Abstract: The invention relates to a novel process for the preparation of Ruthenium metathesis catalysts of the formula Ruthenium metathesis catalysts have been widely applied in the synthesis of macrocyclic drug compounds.

Abstract: An optical recording material comprising at least one kind of chalcone type compound represented by the following general formula (I) or a metal complex using the chalcone type compound as a ligand: wherein ring A represents a 5- or 6-membered heterocyclic ring or an aromatic ring; ring B represents a 5- or 6-membered heterocyclic ring, an aromatic ring, or a metallocene structure; the above-mentioned heterocyclic and aromatic ring may be condensed with other rings or may be substituted; n is 0 or 1.

Abstract: Provided is a colored photosensitive curing composition useful for color filters in primary colors, including blue, green, and red, having a high molar absorption coefficient and allowing a reduction in film thickness and superior color purity and fastness. A colored photosensitive curing composition, comprising, as its colorant, a dipyrromethene-based metal complex compound obtained from a metal or metal compound and a dipyrromethene-based compound represented by the following Formula (I): wherein in Formula (I), R1 to R6 each independently represent a hydrogen atom or a substituent group; and R7 represents a hydrogen or halogen atom, or an alkyl, aryl or heterocyclic group.